Observational analysis reveals distinct serum metabolic profiles in AML patients during initial chemotherapy, suggesting potential biomarkers for drug resistance.
Motivation: Acute myeloid leukemia is marked by complex metabolic adaptations. Identifying metabolic alterations in patients may provide insights into treatment responses. Goal(s): The study aims to explore serum metabolic profiles of newly diagnosed AML patients throughout their initial chemotherapy stages to find potential biomarkers for early drug resistance detection or prognostic predictions. Approach: Using NMR serum metabolomics, serum samples were analyzed from AML patients at different chemotherapy stages. Multivariate statistical analysis, including PCA and OPLS-DA, were employed to detect metabolic differences. Results: Distinct serum metabolic profiles were observed across first chemotherapy stages, primarily including various amino acid metabolism and lipid metabolism. Impact: This study reveals serum metabolic changes in new AML patients during chemotherapy. It identifies distinct metabolic profiles, paving the way for early biomarkers of drug resistance and prognosis. Understanding these mechanisms can enhance treatment strategies and improve patient prognosis.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) studied this question.